4/9
01:12 pm
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Bank of America Co. from $16.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Bank of America Co. from $16.00 to $14.00. They now have a "buy" rating on the stock.
4/8
05:10 pm
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Medium
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
4/8
06:33 am
inzy
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency [Yahoo! Finance]
High
Report
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency [Yahoo! Finance]
4/8
06:30 am
inzy
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
High
Report
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
4/5
06:00 pm
inzy
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2
08:48 am
inzy
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Medium
Report
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/2
08:30 am
inzy
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
Medium
Report
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
3/26
08:42 am
inzy
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 [Yahoo! Finance]
Medium
Report
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 [Yahoo! Finance]
3/26
08:30 am
inzy
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Medium
Report
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
3/18
03:15 pm
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
3/12
02:07 pm
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Low
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
3/12
08:52 am
inzy
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights [Yahoo! Finance]
Medium
Report
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights [Yahoo! Finance]
3/12
08:30 am
inzy
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
Low
Report
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
3/8
02:56 pm
inzy
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward [Seeking Alpha]
Low
Report
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward [Seeking Alpha]
2/26
08:30 am
inzy
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
Medium
Report
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
2/6
08:30 am
inzy
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/30
11:20 am
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Low
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.